Find information on thousands of medical conditions and prescription drugs.

Velcade


Bortezomib (marketed as Velcade™ by Millenium Pharmaceuticals) is a "first-in-class" proteasome inhibitor. It is the best studied of a next generation of anti-myeloma drugs, and is also a potential treatment for plasma cell leukemia. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Bortezomib works by blocking the action of 26S proteasome, which is a multicatalytic enzyme whose function is to degrade abnormal or misfolded proteins targeted for destruction. There is emerging evidence that 26S proteasome plays a role in myeloma and lymphoma.

The Multiple Myeloma Research Foundation was responsible for a substantial amount of the funding for the development and testing of this drug.

Side effects

Bortezomib is associated with peripheral neuropathy in 30% of patients; occasionally, it can be painful. This can be worse in patients with pre-existing neuropathy. In addition, myelosuppression as neutropenia and thrombocytopenia can also occur and be dose limiting.

Links

  • Millenium Pharmaceuticals website on Velcade™
  • International Myeloma Foundation article on Velcade™
  • US Food and Drugs Administration on Velcade™
  • Dedicated website for European audience

Read more at Wikipedia.org


[List your site here Free!]


Millennium Announces Webcast of Data on VELCADE® for Injection From the 47th Annual Meeting of the American Society of Hematology
From PR Newswire, 12/8/05

CAMBRIDGE, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. will hold a live webcast of its conference call at 8:00 a.m. EST on Wednesday, December 14, 2005. Millennium management will discuss VELCADE data from the 47th Annual Meeting of the American Society of Hematology being held in Atlanta, GA from December 10-13, 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The live webcast can be accessed by visiting the Investors section of the Company's website, http://www.millennium.com/. Following the webcast, an archived version of the call will be available at the same address for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com/.

CONTACT: Kyle Kuvalanka of Millennium Pharmaceuticals, Inc., +1-617-761-4734

Web site: http://www.millennium.com/

Company News On-Call: http://www.prnewswire.com/comp/114562.html

COPYRIGHT 2005 PR Newswire Association LLC
COPYRIGHT 2005 Gale Group

Return to Velcade
Home Contact Resources Exchange Links ebay